CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form URL: http://www.jmir.org/2011/4/e126/ doi: 10.2196/jmir.1923 PMID: 22209829 s0975835@gmail.com 切換帳戶 **〉** 必須重新提交才能儲存 ★ 未共用的項目 *表示必填問題 Your name * First Last Shu-Cheng Lin Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada Tainan university of tecnology, Tainan, Taiwan Your e-mail address * abc@gmail.com s0975835@gmail.com Title of your manuscript * Provide the (draft) title of your manuscript. Exploring the Impact of Fruit and Vegetable Enzyme Supplementation on Aerobic

Performance and Lactate Response in the Elderly Following High-Intensity Interval Exercise Combine Exergaming: Usability Study

0 版上0.09	CONCORT-ETIEAETT (V 1.5.1) - Cubinission/i ubilcation i om
Name of your App/Software/Ir If there is a short and a long/alte name in brackets.	ntervention * ernate name, write the short name first and add the long
Windows 11	
Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", 您的回答	"Version 2.0.27913"
Language(s) * What language is the interventio comma (e.g. "English, French") English, Tradionnal Chinese	n/app in? If multiple languages are available, separate by
	osite or App op on app in appstore (itunes, Google Play), or URL of the OVD or hardware, you can also link to an Amazon page.
URL of an image/screenshot 您的回答	(optional)

Accessibility * Can an enduser access the intervention presently?
 access is free and open access only for special usergroups, not open access is open to everyone, but requires payment/subscription/in-app purchases app/intervention no longer accessible 其他:
Primary Medical Indication/Disease/Condition * e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)" elderly female participants
Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial Results indicated that enzyme supplementatio
Secondary/other outcomes Are there any other outcomes the intervention is expected to affect? the analysis of training impulse, encompassing both objective and subjective measures of training load, revealed no significant differences between the enzyme and placebo groups post-supplementation.

Recommended "Dose" *
What do the instructions for users say on how often the app should be used?
Approximately Daily
Approximately Weekly
Approximately Monthly
Approximately Yearly
as needed"
● 其他: fruit and vegetable enzyme supplement at a dosage of 30 c.c. twice d
Approx. Percentage of Users (starters) still using the app as recommended after * 3 months
unknown / not evaluated
0-10%
O 11-20%
21-30%
31-40%
41-50%
51-60%
61-70%
71%-80%
81-90%
91-100%
○ 其他:

!

Overall, was the app/intervention effective? *
yes: all primary outcomes were significantly better in intervention group vs control
partly: SOME primary outcomes were significantly better in intervention group vs control
on statistically significant difference between control and intervention
outcomes potentially harmful: control was significantly better than intervention in one or more
inconclusive: more research is needed
 其他:
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
At which stage in your article preparation are you currently (at the time you fill in this form)
At which stage in your article preparation are you currently (at the time you fill in this form) Onot submitted yet - in early draft status
At which stage in your article preparation are you currently (at the time you fill in this form) onot submitted yet - in early draft status not submitted yet - in late draft status, just before submission
At which stage in your article preparation are you currently (at the time you fill in this form) onot submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments

Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")
onot submitted yet / unclear where I will submit this
Journal of Medical Internet Research (JMIR)
JMIR mHealth and UHealth
JMIR Serious Games
JMIR Mental Health
JMIR Public Health
JMIR Formative Research
Other JMIR sister journal
○ 其他:
Is this a full powered effectiveness trial or a pilot/feasibility trial? *
Is this a full powered effectiveness trial or a pilot/feasibility trial? * Pilot/feasibility
Pilot/feasibility
Pilot/feasibility
Pilot/feasibilityFully powered
 Pilot/feasibility Fully powered Manuscript tracking number * If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of
Pilot/feasibility Fully powered Manuscript tracking number * If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

1

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

$\overline{}$	

yes

-	
_	
l .	- 1

其他:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

1

2

3

5

subitem not at all important

 \bigcirc

0

0

) essential

清除選取的項目

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The exergaming used in this study was Nintendo switch. Fruit and vegetable enzyme supplement at a dosage of 30 c.c. twice daily over a period of 14 days.

!

1a-ii) Non-web-based compor		•				
Mention non-web-based compor "with telephone support").	nents or	importar	nt co-inte	ervention	s in title,	if any (e.g.,
	1	2	3	4	5	
subitem not at all important	0	0	•	0	0	essential
					ì	青除選取的項目
Does your paper address sub	item 1a	-ii?				
Copy and paste relevant sections "like this" to indicate direct quot providing additional information applicable/relevant for your students.	es from not in th	your mai	nuscript)	, or elabo	rate on t	his item by
您的回答						
1a-iii) Primary condition or tar Mention primary condition or tar Diabetes") Example: A Web-base Children with Type I Diabetes: Ra	get grou ed and M	ip in the t obile Int	itle, if an erventior	n with Tel		
Mention primary condition or tar Diabetes") Example: A Web-base	get grou ed and M	ip in the t obile Int	itle, if an erventior	n with Tel		
Mention primary condition or tar Diabetes") Example: A Web-base	get grou ed and M andomize	ip in the t lobile Inte ed Contro	itle, if an erventior olled Tria	n with Tel	lephone \$	
Mention primary condition or tar Diabetes") Example: A Web-base Children with Type I Diabetes: Ra	get grou ed and M andomize	ip in the t lobile Inte ed Contro	itle, if an erventior olled Tria	n with Tel	5	Support for
Mention primary condition or tar Diabetes") Example: A Web-base Children with Type I Diabetes: Ra	get grou ed and M andomize	ip in the t lobile Inte ed Contro	itle, if an erventior olled Tria	n with Tel	5	Support for essential
Mention primary condition or tar Diabetes") Example: A Web-base Children with Type I Diabetes: Ra	get grou ed and M andomize	ip in the to the following in the total in t	itle, if an erventior olled Tria	n with Tel	5	Support for essential
Mention primary condition or tar Diabetes") Example: A Web-base Children with Type I Diabetes: Ra subitem not at all important	rget grouped and Mandomize 1 O iitem 1a s from mes from not in the	p in the tool to t	ot title (ir	a with Tell	sotes in quarte on t	essential 青除選取的項目 uotation marks his item by

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important

O O O essential

清除選取的項目

Does your paper address subitem 1b-i?*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Exergaming is just a tool that focuses on course planning and explores the impact of vegetable and fruit enzyme supplementation on post-exercise physiology

Clarify the level of human involve automated" vs. "therapist/nurse expertise of providers involved, paper is reporting. If this inform adding it)	rement in e/care pro if any). (I	the abst ovider/ph Note: Onl	tract, e.g. nysician-a y report i	, use phr assisted" n the abs	ases like (mentior stract wh	"fully n number and at the main
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address subitem 1b-ii? Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study						or elaborate on
1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)						
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does y	our/	paper	address	subitem	1b-iii?
--------	------	-------	---------	---------	---------

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important

 \mathcal{C}

)

0

) essential

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important O O O O essential

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

1 2 3 4 5
subitem not at all important O O O o essential

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The subjects of this study were healthy elderly women

2a-ii) Scientific background, rationale: What is known about the (type of) system Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

subitem not at all important U U essential

清除選取的項目

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We hope to provide a new option for physical training through the fun and training arrangements of Exergaming. And reduce the negative effects of exercise through the supplement of vegetable and fruit enzymes

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our paper has nothing to do with

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study adopts a random, crossover, and independent sample experimental design to compare the effects of Nintendo Switch Ring-Con combined with HIIE on exercise physiology, and explore whether supplementing with vegetable and fruit enzymes can reduce the negative effects of exercise.

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does v	our	paper	address	CONSORT	subitem	3b? *
--------	-----	-------	---------	---------	---------	-------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All participants reported a regular exercise habit (3 times per week within the past year). They also completed the Physical Activity Readiness Questionnaire and confirmed no history of upper limb skeletal muscle injury or major injury. Participants were instructed to avoid strenuous activities and the intake of caffeine or muscle-enhancing supplements for 24 hours prior to the experiment.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

subitem not at all important O O O o essential

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Our paper has nothing to do with

4a-i) Computer / Internet literacy Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified. 1 2 3 4 5 subitem not at all important O O O O essential

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 4a-ii? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study								
Our paper has nothing to do wit	h							
4a-iii) Information giving duri Information given during recrui recruitment and in the informed documentation as appendix, se user self-selection, user expect	tment. Sp d consent ee also ite	pecify how t procedu em X26),	ıres (e.g. as this ir	, publish Iformatio	the inforn	ned consent		
subitem not at all important	1	2	3	4	5	essential		
Does your paper address su Copy and paste relevant sectio "like this" to indicate direct quo providing additional informatio applicable/relevant for your stu	ns from totes from n not in th	he manu your ma	nuscript)	, or elabo	orate on t	his item by		
4h) Settings and locations w	horo tho	datawa	vro collo	otod				

Does your paper address CONSORT subitem 4b? *											
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study											
Our paper has nothing to do with											
4b-i) Report if outcomes were (self-)assessed through online questionnaires Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.											
	1	2	3	4	5						
subitem not at all important	0	0	0	0	0	essential					
Does your paper address subitem 4b-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Our paper has nothing to do with											
4b-ii) Report how institutional affiliations are displayed Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)											
	1	2	3	4	5						
subitem not at all important											

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

- 5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
- 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

2 3 4 5

subitem not at all important OOOOO essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 2 3 4 5

subitem not at all important

essential

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

2 3 4

subitem not at all important OOOOO essential

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

Provide information on quality a information provided [1], if appli		e method	ls to ens	ure accu	racy and	quality of
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stud	ns from tl tes from n not in th	he manus your ma	nuscript)	, or elabo	orate on t	his item by
您的回答						
5-v) Ensure replicability by pu	_				-	_
5-v) Ensure replicability by puscreenshots/screen-capture vused Ensure replicability by publishin capture video, and/or providing researchers should in principle reporting.	video, an	nd/or pro urce code	oviding f e, and/or algorithr	lowchar providing ns used.	ts of the g screens Replicab	algorithms shots/screen- pility (i.e., other
screenshots/screen-capture vised Ensure replicability by publishin capture video, and/or providing researchers should in principle	video, an	nd/or pro urce code	oviding f e, and/or algorithr	lowchar providing ns used.	ts of the g screens Replicab	algorithms shots/screen- pility (i.e., other
screenshots/screen-capture vised Ensure replicability by publishin capture video, and/or providing researchers should in principle	video, and g the soul flowchar be able to	nd/or pro urce code ts of the o replicat	oviding f e, and/or algorithr e the stu	lowchar providing ms used. idy) is a l	ts of the g screens Replicab nallmark	algorithms shots/screen- pility (i.e., other

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

1 2 3 4 5
subitem not at all important O O o o essential

清除選取的項目

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all important O O essential

清除選取的項目

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants must be healthy

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

1 2 3 4 5
subitem not at all important O O O essential

清除選取的項目

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We hope to organize sports training through the concept of behavior change technology and the fun of sports games. And combined with vegetable and fruit enzyme supplements, it can be used as a supplement strategy in the future

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

1 2 3 4 5

subitem not at all important

0 0 0 0

essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

2 3 4

subitem not at all important O O O essential

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5
subitem not at all important O O essential

清除選取的項目

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The intensity of this research is recommended to be carried out to the best of one's own efforts, so there is no classification.

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

1 2 3 4 5
subitem not at all important O O O O essential

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The 16 participants underwent the Exergaming HIIE test as an initial assessment (pre-test). Participants engaged in a 5-minute warm-up on a stationary bike, followed by HIIE using the Nintendo Switch Ring Fit Adventure design. The training method was adapted from the research of [8, 9] and consisted of 8 sets of 20 seconds of maximum effort exercise with 30 seconds of complete rest between each set, resulting in a total exercise time of 370 seconds. The HIIE design incorporated training modes targeting the deltoid, pectoralis major, latissimus dorsi, and quadriceps muscles in the Nintendo Switch Ring Fit Adventure. Blood lactate levels, heart rate, and ratings of perceived exertion were recorded before, during, and after exercise, and training load was quantified using TRIMP. Participants were matched and divided into two groups, the enzyme group, and the placebo group, based on their blood lactate levels during HIIE. Each group comprised 8 individuals. Supplementation with vegetable and fruit enzymes or maltodextrin commenced three days after the pre-test and lasted for a total of 14 days. On the 14th day, following the completion of supplementation, the participants underwent the Exergaming HIIE test as a post-test.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stu-	ns from th tes from n not in th dy	ne manus your mai	script (in nuscript)	, or elabo	orate on t	his item by			
6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].									
subitem not at all important	1	2	3	4	5	essential			
Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text 您的回答									
6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.									
subitem not at all important	1	2	3	4	5	essential			

Does your paper address sul Copy and paste relevant section			ot text			
您的回答						
6a-iii) Describe whether, how obtained Describe whether, how, and whe (e.g., through emails, feedback)	en qualita	Itive feed	back fro	m partici	·	·
(e.g., allough emails, recubuok	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant section 您的回答			ot text			
6b) Any changes to trial outco	omes af	ter the tr	ial com	menced,	with rea	asons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study investigated the effects of enzyme supplementation on lactate response and heart rate in elderly individuals engaging in a combination of exergaming and high-intensity interval exercise (HIIE). Results indicated that enzyme supplementation significantly reduced blood lactate levels post-exercise, particularly after the 4th and 8th exercise bouts, demonstrating the potential of enzymes to mitigate exercise-induced lactate accumulation. Despite a notable increase in heart rate during the exercise sessions, which surpassed 85% of the estimated maximum for elderly participants, there was no discernible difference in heart rate responses between the enzyme and placebo groups, either before or after supplementation. Furthermore, the analysis of training impulse, encompassing both objective and subjective measures of training load, revealed no significant differences between the enzyme and placebo groups post-supplementation. This suggests that while enzyme supplementation may aid in lactate management, it does not significantly impact the overall perceived intensity or cardiovascular demand of HIIE combined with exergaming in elderly individuals.

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

If the subject feels any discomfort, the experiment can be stopped immediately; this problem was not encountered in this study

8a) Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study does not have this problem

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study does not have this problem

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

sequentially numbered containers

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Conducted by experimental team

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering cointerventions (if any).

1 2 3 4 5
subitem not at all important O O o o essential

清除選取的項目

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study adopted a single-blind design. The subjects did not know whether they were taking supplements or placebos. Only the experimenter knew.

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

1 2 3 4 5
subitem not at all important O O O o essential

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

11b) If relevant, description of the similarity of interventions (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The supplements consumed in this study are all nationally certified safe foods, including vegetable and fruit enzymes or maltose.

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All the data were analyzed by SPSS for Windows 20.0. Data are expressed as the mean \pm standard deviation (SD) and 95% confidence interval (95% CI). A mixed design two-way analysis of variance (ANOVA) (group × time) was used to compare the variables of lactate, heart rate and training impulse between two groups before and after the 14-days of supplementation. Graphs were generated using GraphPad Prism 8.0 (GraphPad Software, San Diego, California, USA). Cohen's conventions for ES (Cohen d) were calculated by the G*Power 3.1 software program (Heinrich-Heine-Universität, Düsseldorf, Germany), where the ESs of 0.2, 0.5, and 0.8 are considered small, medium, and large, respectively. Statistical significance was set as p < 0.05.

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

subitem not at all important

O O O essential

清除選取的項目

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study does not have this problem

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study does not have this problem

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

1 2 3 4

subitem not at all important OOOO

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

essential

x26-ii) Outline informed conse	ent proc	edures				
Outline informed consent proce Checkbox, etc.?), and what infor be included in informed consent	mation v	vas prov				•
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant section "like this" to indicate direct quot providing additional information applicable/relevant for your stud	s from th tes from not in th	ne manu your ma	nuscript)	, or elab	orate on 1	this item by
X26-iii) Safety and security posafety and security procedures, the likelihood or detection of ha	incl. priv	acy cons				
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant section "like this" to indicate direct quot providing additional information applicable/relevant for your stud	s from th tes from not in th	ne manu your ma	nuscript)	, or elab	orate on 1	this item by

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After recruiting a total of 30 healthy elderly participants, and following screening and explanation, 12 individuals did not meet the inclusion criteria, and 2 politely declined to participate. Ultimately, 16 female elderly participants were recruited for this study. Consequently, a single-blind, randomized matched-pair design was employed to allocate the 16 participants into two groups: the enzyme group and the placebo group.

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram)

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After recruiting a total of 30 healthy elderly participants, and following screening and explanation, 12 individuals did not meet the inclusion criteria, and 2 politely declined to participate. Ultimately, 16 female elderly participants were recruited for this study. Consequently, a single-blind, randomized matched-pair design was employed to allocate the 16 participants into two groups: the enzyme group and the placebo group.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

1 2 3 4 5

subitem not at all important

) \circ \circ

0

 \bigcirc

essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Recruitment date for this study is 2023

14a-i) Indicate if critical "secular event Internet resources available or "resources"	s" fell int	to the stu	ıdy perio	d, e.g., si	gnificant	•
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Stop the experiment after the experiment is over

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

15 healthy elderly women. All participants reported a regular exercise habit (3 times per week within the past year). They also completed the Physical Activity Readiness Questionnaire and confirmed no history of upper limb skeletal muscle injury or major injury.

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

1 2 3 4 5

subitem not at all important

 \supset

0

 \bigcirc

)

essential

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study does not have this problem

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide
--

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

1 2 3 4 5
subitem not at all important O O O o essential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sample size computation was based on the study by Flanagan and Jakeman [29]. Based on a statistical power analysis, a total sample size of 16 participants (8 per group) was needed to achieve a statistical power of 0.8 to detect a large effect size (ES) for supplement-time interaction at an alpha level of 0.05[30].

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

1 2 3 4 5
subitem not at all important O O O O essential

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study used statistical methods to conduct statistical analysis and calculate the effect size

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

1 2 3 4 5

subitem not at all important O O O essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study used statistical methods to conduct statistical analysis and calculate the effect size

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study did not use other

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

1 2 3 4 5

subitem not at all important

O O O o essential

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no other accidental injuries in this experiment

19-i	Include	privacy	breaches,	technical	problems
101	illolaac	privac	, bicaciico,	, toorii iloar	problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

1 2 3 4 5

subitem not at all important

O O O o essential

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

1 2 3 4 5

subitem not at all important OOOOO essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

subitem not at all important O O o o essential

清除選取的項目

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study investigated the effects of enzyme supplementation on lactate response and heart rate in elderly individuals engaging in a combination of exergaming and high-intensity interval exercise (HIIE). Results indicated that enzyme supplementation significantly reduced blood lactate levels post-exercise, particularly after the 4th and 8th exercise bouts, demonstrating the potential of enzymes to mitigate exercise-induced lactate accumulation. Despite a notable increase in heart rate during the exercise sessions, which surpassed 85% of the estimated maximum for elderly participants, there was no discernible difference in heart rate responses between the enzyme and placebo groups, either before or after supplementation. Furthermore, the analysis of training impulse, encompassing both objective and subjective measures of training load, revealed no significant differences between the enzyme and placebo groups post-supplementation. This suggests that while enzyme supplementation may aid in lactate management, it does not significantly impact the overall perceived intensity or cardiovascular demand of HIIE combined with exergaming in elderly individuals.

22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research.							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	
Does your paper address sub Copy and paste relevant section "like this" to indicate direct quot providing additional information applicable/relevant for your stud	s from thes from not in th	ne manus your mai	nuscript)	, or elabo	orate on t	his item by	
20) Trial limitations, addressir relevant, multiplicity of analys	•	es of po	otential b	oias, imp	orecision	, and, if	
20-i) Typical limitations in ehe Typical limitations in ehealth tria trials often look at a multiplicity biases due to non-use of the inte consent procedures, unexpected	ils: Partion of outco ervention d events.	cipants ir mes, inc ı/usabilit	reasing r y issues,	isk for a biases t	Type I err hrough in	or. Discuss	
subitem not at all important	1	2	3	4	5	essential	

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study does not have this problem

21) Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

1 2 3 4

subitem not at all important







0

essential

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other cointerventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

1 2 3 4 5

subitem not at all important

0

 \bigcirc

essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The human research ethics committee of the local university approved this study, which was also approved by the human research ethics committee of the National Cheng Kung University, Taiwan. (Approval No. NCKU HREC-E-112-419-2). Users volunteered for this study and agreed to participate by signing an informed consent form.

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study is the first submission and can be viewed in the journal

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Financial support provided by the Taiwan Ministry of Education's "Industry Academy Program" and grant of Tainan University of Technology.

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1 2 3 4 5

subitem not at all important OOOOOO essential

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

About the CONSORT EHEALTH checklist

As	a result	of us	sing t	nis c	checklist,	did	you	make	change	s in	your	manu	script?	*

- yes, major changes
- yes, minor changes
- O no

What were the most important changes you made as a result of using this checklist?

您的回答

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript

*

It will take about a week to revise

As a result of using this checklist, do you think your manuscript has improved? *
yes
O no
 其他:
Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
O yes
O no
 其他:
Any other comments or questions on CONSORT EHEALTH
您的回答
STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.
When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.
Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!
Final step: Click submit! Click submit so we have your answers in our database!

! 提交

請勿利用 Google 表單送出密碼。

Google 並未認可或建立這項内容。 檢舉濫用情形 - 服務條款 - 隱私權政策

Google 表單

1